Fleury Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Fleury wird ein jährliches Gewinn- und Umsatzwachstum von 14% bzw. 6.5% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 11.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 16.9% betragen.

Wichtige Informationen

14.0%

Wachstumsrate der Gewinne

11.7%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	26.9%
Wachstumsrate der Einnahmen	6.5%
Zukünftige Eigenkapitalrendite	16.9%
Analystenabdeckung	Good
Zuletzt aktualisiert	23 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

We Think Fleury's (BVMF:FLRY3) Profit Is Only A Baseline For What They Can Achieve

Nov 15

Fleury S.A. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Feb 28

What Type Of Shareholders Make Up Fleury S.A.'s (BVMF:FLRY3) Share Registry?

Feb 15

Shareholders of Fleury (BVMF:FLRY3) Must Be Delighted With Their 360% Total Return

Feb 02

Three Days Left To Buy Fleury S.A. (BVMF:FLRY3) Before The Ex-Dividend Date

Jan 03

Should We Be Excited About The Trends Of Returns At Fleury (BVMF:FLRY3)?

Dec 28

Would Fleury S.A. (BVMF:FLRY3) Be Valuable To Income Investors?

Dec 12

Taking A Look At Fleury S.A.'s (BVMF:FLRY3) ROE

Nov 29

Getting In Cheap On Fleury S.A. (BVMF:FLRY3) Might Be Difficult

Aug 30

Here's What You Should Know About Fleury S.A.'s (BVMF:FLRY3) 3.8% Dividend Yield

Aug 18

Can Fleury S.A. (BVMF:FLRY3) Improve Its Returns?

Aug 03

Gewinn- und Umsatzwachstumsprognosen

BOVESPA:FLRY3 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (BRL Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	8,831	870	908	1,631	7
12/31/2025	8,339	774	881	1,492	9
12/31/2024	7,773	660	834	1,336	5
9/30/2024	7,550	614	1,363	1,791	N/A
6/30/2024	7,457	597	1,311	1,713	N/A
3/31/2024	7,138	498	1,037	1,447	N/A
12/31/2023	6,471	424	1,025	1,439	N/A
9/30/2023	5,881	373	899	1,291	N/A
6/30/2023	5,158	295	749	1,159	N/A
3/31/2023	4,610	291	719	1,137	N/A
12/31/2022	4,463	308	574	987	N/A
9/30/2022	4,366	348	518	989	N/A
6/30/2022	4,248	347	440	895	N/A
3/31/2022	4,069	342	454	882	N/A
12/31/2021	3,873	350	605	1,019	N/A
9/30/2021	3,783	419	713	1,016	N/A
6/30/2021	3,629	456	692	936	N/A
3/31/2021	3,151	317	517	715	N/A
12/31/2020	2,972	257	459	647	N/A
9/30/2020	2,764	174	398	577	N/A
6/30/2020	2,645	133	467	656	N/A
3/31/2020	2,918	278	565	755	N/A
12/31/2019	2,905	312	524	732	N/A
9/30/2019	2,840	314	467	740	N/A
6/30/2019	2,767	314	329	659	N/A
3/31/2019	2,712	328	364	706	N/A
12/31/2018	2,664	332	376	701	N/A
9/30/2018	2,592	338	317	601	N/A
6/30/2018	2,524	334	N/A	598	N/A
3/31/2018	2,449	335	N/A	548	N/A
12/31/2017	2,383	321	N/A	530	N/A
9/30/2017	2,324	331	N/A	550	N/A
6/30/2017	2,248	307	N/A	541	N/A
3/31/2017	2,176	266	N/A	547	N/A
12/31/2016	2,096	229	N/A	540	N/A
9/30/2016	2,046	180	N/A	526	N/A
6/30/2016	2,002	152	N/A	494	N/A
3/31/2016	1,956	139	N/A	440	N/A
12/31/2015	1,895	107	N/A	369	N/A
9/30/2015	1,845	94	N/A	337	N/A
6/30/2015	1,801	90	N/A	285	N/A
3/31/2015	1,730	73	N/A	262	N/A
12/31/2014	1,679	86	N/A	286	N/A
9/30/2014	1,646	73	N/A	275	N/A
6/30/2014	1,634	60	N/A	240	N/A
3/31/2014	1,659	66	N/A	201	N/A
12/31/2013	1,657	61	N/A	210	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: FLRY3Das prognostizierte Gewinnwachstum (14% pro Jahr) liegt über der Sparquote (10.4%).

Ertrag vs. Markt: FLRY3Die Erträge des Unternehmens (14% pro Jahr) werden voraussichtlich schneller wachsen als der Markt BR (12.6% pro Jahr).

Hohe Wachstumserträge: FLRY3Die Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: FLRY3Die Einnahmen des Unternehmens (6.5% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt BR (7.4% pro Jahr).

Hohe Wachstumseinnahmen: FLRY3Die Einnahmen des Unternehmens (6.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: FLRY3Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (16.9%).

Fleury Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates increase by 10%, revenue downgraded

Consensus EPS estimates fall by 15%

Consensus EPS estimates increase by 14%

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

Recent updates

We Think Fleury's (BVMF:FLRY3) Profit Is Only A Baseline For What They Can Achieve

Third quarter 2024 earnings: Revenues miss analyst expectations

Fleury (BVMF:FLRY3) Seems To Use Debt Quite Sensibly

Fleury S.A.'s (BVMF:FLRY3) Price Is Out Of Tune With Earnings

Second quarter 2024 earnings released

Now 20% undervalued

We Think Fleury (BVMF:FLRY3) Can Stay On Top Of Its Debt

First quarter 2024 earnings released

The Price Is Right For Fleury S.A. (BVMF:FLRY3)

Concerns Surrounding Fleury's (BVMF:FLRY3) Performance

Upcoming dividend of R$0.15 per share

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 22% undervalued after recent price drop

Fleury S.A. to Report Q3, 2024 Results on Nov 07, 2024

Earnings Tell The Story For Fleury S.A. (BVMF:FLRY3)

Consensus EPS estimates increase by 10%, revenue downgraded

Third quarter 2023 earnings: Revenues in line with analyst expectations

Fleury (BVMF:FLRY3) Has A Pretty Healthy Balance Sheet

Consensus EPS estimates fall by 15%

Consensus EPS estimates increase by 14%

Second quarter 2023 earnings: Revenues in line with analyst expectations

Does Fleury (BVMF:FLRY3) Have A Healthy Balance Sheet?

New major risk - Shareholder dilution

Fleury S.A. to Report Q3, 2023 Results on Nov 09, 2023

First quarter 2023 earnings: Revenues exceed analyst expectations

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

We Think Fleury (BVMF:FLRY3) Can Stay On Top Of Its Debt

Less than half of directors are independent

Consensus forecasts updated

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analyst expectations

Fleury S.A. (BOVESPA:FLRY3) completed the acquisition of Methodos laboratory in Minas Gerais.

At R$18.27, Is It Time To Put Fleury S.A. (BVMF:FLRY3) On Your Watch List?

Does Fleury (BVMF:FLRY3) Have A Healthy Balance Sheet?

Second quarter 2022 earnings: Revenues exceed analyst expectations

Fleury (BVMF:FLRY3) Has Some Way To Go To Become A Multi-Bagger

Investor sentiment improved over the past week

Less than half of directors are independent

When Should You Buy Fleury S.A. (BVMF:FLRY3)?

First quarter 2022 earnings: Revenues exceed analyst expectations

Is Fleury (BVMF:FLRY3) Using Too Much Debt?

Return Trends At Fleury (BVMF:FLRY3) Aren't Appealing

Now 24% undervalued after recent price drop

Consensus forecasts updated

Price target decreased to R$20.75

Now 22% undervalued after recent price drop

Fleury S.A. to Report Fiscal Year 2021 Results on Mar 17, 2022

At R$19.12, Is It Time To Put Fleury S.A. (BVMF:FLRY3) On Your Watch List?

Now 20% undervalued after recent price drop

High number of new directors

Price target decreased to R$23.18

Returns On Capital Are Showing Encouraging Signs At Fleury (BVMF:FLRY3)

Fleury (BVMF:FLRY3) Seems To Use Debt Quite Sensibly

Price target decreased to R$26.38

Is Fleury S.A. (BVMF:FLRY3) Potentially Undervalued?

Investors Should Be Encouraged By Fleury's (BVMF:FLRY3) Returns On Capital

Fleury (BVMF:FLRY3) Seems To Use Debt Rather Sparingly

Second quarter 2021 earnings released

Is It Time To Consider Buying Fleury S.A. (BVMF:FLRY3)?

Consensus EPS estimates increase to R$1.19

First quarter 2021 earnings released

Does Fleury (BVMF:FLRY3) Have A Healthy Balance Sheet?

Fleury (BVMF:FLRY3) Shareholders Will Want The ROCE Trajectory To Continue

At R$25.16, Is It Time To Put Fleury S.A. (BVMF:FLRY3) On Your Watch List?

Should You Or Shouldn't You: A Dividend Analysis on Fleury S.A. (BVMF:FLRY3)

Analysts update estimates

New 90-day low: R$25.63

Only One Day Left To Cash In On Fleury's (BVMF:FLRY3) Dividend

Revenue and earnings beat expectations